Relapse in guillain-barré syndrome after treatment with human immune globulin

D. N. Irani, D. R. Cornblath, V. Chaudhry, C. Borel, D. F. Hanley

Research output: Contribution to journalArticlepeer-review

Abstract

Seven adult patients received human immune globulin intravenously as initial therapy for Guillain-Barré syndrome. Although all patients initially stabilized or improved, five patients deteriorated 1 to 16 days after completion of treatment. In all five patients, clinical worsening included loss of at least one functional grade together with a decreased forced vital capacity. We subsequently treated each patient with a course of plasma exchange, which led to varying degrees of clinical improvement in four. In contrast to previously reported relapse rates for Guillain-Barré syndrome, our experience suggests that clinically significant relapses may occur in patients more often following human immune globulin therapy than after either plasma exchange or no therapy.

Original languageEnglish (US)
Pages (from-to)872-875
Number of pages4
JournalNeurology
Volume43
Issue number5
StatePublished - May 1993

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Relapse in guillain-barré syndrome after treatment with human immune globulin'. Together they form a unique fingerprint.

Cite this